TY - JOUR
T1 - Transplantation of islets of langerhans in patients with insulin-dependent diabetes mellitus
AU - Alejandro, R.
N1 - Funding Information:
This work was supported by National Institutes of Health grants DK25802 and DK 07346 and the Diabetes Research Institute Foundation.
PY - 1995
Y1 - 1995
N2 - From 1974 to December, 1992, as reported by the International Islet Transplant Registry, there have been 175 adult islet allografts worldwide. Ninety-eight of these transplants have been performed since 1989. Eleven patients with Type I diabetes mellitus who have received islet allografts since 1989 have achieved insulin-independence for variable periods of time. As of June, 1993, four patients remain insulin-independent (from >127 to >326 days). Insulin-independence after human islet cell transplantation is not yet a consistent achievement. Several key issues in pancreas procurement, islet cell isolation, islet preservation, islet engraftment and the prevention of islet allograft rejection still need to be addressed. The expansion of current clinical trials should be limited to patients who are taking or who require immunosuppressive drugs for other reasons (kidney or liver transplant recipient) since the risks of chronic immunosuppression probably outweight the risks from chronic diabetes, although as we are able to induce a more specific state of immunosuppression this rationale may become debatable.
AB - From 1974 to December, 1992, as reported by the International Islet Transplant Registry, there have been 175 adult islet allografts worldwide. Ninety-eight of these transplants have been performed since 1989. Eleven patients with Type I diabetes mellitus who have received islet allografts since 1989 have achieved insulin-independence for variable periods of time. As of June, 1993, four patients remain insulin-independent (from >127 to >326 days). Insulin-independence after human islet cell transplantation is not yet a consistent achievement. Several key issues in pancreas procurement, islet cell isolation, islet preservation, islet engraftment and the prevention of islet allograft rejection still need to be addressed. The expansion of current clinical trials should be limited to patients who are taking or who require immunosuppressive drugs for other reasons (kidney or liver transplant recipient) since the risks of chronic immunosuppression probably outweight the risks from chronic diabetes, although as we are able to induce a more specific state of immunosuppression this rationale may become debatable.
KW - Diabetes mellitus
KW - Islets allografts
KW - Islets of Langerhans
KW - Transplantation
UR - http://www.scopus.com/inward/record.url?scp=0028916562&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028916562&partnerID=8YFLogxK
U2 - 10.3109/00365529509107773
DO - 10.3109/00365529509107773
M3 - Article
C2 - 7777792
AN - SCOPUS:0028916562
VL - 30
SP - 125
EP - 128
JO - Scandinavian Journal of Gastroenterology
JF - Scandinavian Journal of Gastroenterology
SN - 0036-5521
IS - S208
ER -